Back to results
US 2017/0304329 A1Published application
Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug
AssigneeUniversity of Kansas
InventorsSCOTT J WEIR, SHRIKANT ANANT
Life of this patent
Estimating the term…
Abstract
A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer. The ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug can be administered in a therapeutically effective amount.
Claims37
A method of treating bladder cancer, the method comprising:
- providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof;
- and
- administering the pharmaceutical composition to a subject having the bladder cancer,
- wherein:
- R1-R12 each independently include one or more of hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- R13-R14 each independently include one or more of a positive ion, sodium ion, hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- n is 0-20 substituted or unsubstituted;
- and
- m is 0, 1 or 2.
6 more elements
A method of treating bladder cancer in an upper urinary tract, the method comprising:
- providing a pharmaceutical composition having ciclopirox, ciclopirox olamine, or a ciclopirox prodrug represented by a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof;
- and
- administering the pharmaceutical composition to a subject having the bladder cancer in the upper urinary tract,
- wherein:
- R1-R12 each independently include one or more of hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- R13-R14 each independently include one or more of a positive ion, sodium ion, hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- n is 0-20 substituted or unsubstituted;
- and
- m is 0, 1 or 2.
6 more elements
Use of a compound for making a medicament for treating bladder cancer, the compound comprising ciclopirox, ciclopirox olamine, or a ciclopirox prodrug, the ciclopirox prodrug having a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof;
- and
- wherein:
- R1-R12 each independently include one or more of hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- R13-R14 each independently include one or more of a positive ion, sodium ion, hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- n is 0-20 substituted or unsubstituted;
- and
- m is 0, 1 or 2.
4 more elements
A composition for treating bladder cancer, the composition comprising:
- a therapeutically effective amount of ciclopirox, ciclopirox olamine, or a ciclopirox prodrug represented by a structure of Formula 1 or stereoisomer thereof or pharmaceutically acceptable salt thereof for treatment of bladder cancer;
- wherein:
- R1-R12 each independently include one or more of hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- R13-R14 each independently include one or more of a positive ion, sodium ion, hydrogen, halogens, hydroxyls, alkoxys, straight aliphatics, branched aliphatics, cyclic aliphatics, substituted aliphatics, unsubstituted aliphatics, saturated aliphatics, unsaturated aliphatics, aromatics, polyaromatics, substituted aromatics, hetero-aromatics, amines, primary amines, secondary amines, tertiary amines, aliphatic amines, carbonyls, carboxyls, amides, esters, amino acids, peptides, polypeptides, substituted or unsubstituted, or combinations thereof;
- n is 0-20 substituted or unsubstituted;
- and
- m is 0, 1 or 2.
4 more elements
Dependencies are inferred from the claim text.